Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lindenmayer, J.-P. Articles by Lieberman, J. A. Search for Related Content PubMed Citation Articles by Lindenmayer, J.-P. Articles by Lieberman, J. A. Neuroendocrinology Schizophrenia Spectrum Disorders Atypical Neuroleptics Conventional Neuroleptics

Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics

OBJECTIVE: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors’ goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. METHOD: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospitals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. RESULTS: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). CONCLUSIONS: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.

This article has been cited by other articles:

				M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis The British Journal of Psychiatry, June 1, 2008; 192(6): 406 - 411. [Abstract] [Full Text] [PDF]

				M. Weber, M. Colon, and M. Nelson Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia Journal of the American Psychiatric Nurses Association, January 1, 2008; 13(6): 353 - 359. [Abstract] [PDF]

				K. Ojala, E. Repo-Tiihonen, J. Tiihonen, and L. Niskanen Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents J Psychopharmacol, January 1, 2008; 22(1): 33 - 38. [Abstract] [PDF]

				L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics Ann. Pharmacother., October 1, 2007; 41(10): 1593 - 1603. [Abstract] [Full Text] [PDF]

				M. OLFSON, S. C. MARCUS, P. COREY-LISLE, A.S. TUOMARI, P. HINES, and G. J. L'ITALIEN Dr. Olfson and Colleagues Reply Am J Psychiatry, March 1, 2007; 164(3): 526 - 526. [Full Text] [PDF]

				F. RICO-VILLADEMOROS and E. P. CALANDRE Confounding by Indication and the Risk of Hyperlipidemia in Observational Studies of Antipsychotics Am J Psychiatry, March 1, 2007; 164(3): 525 - 526. [Full Text] [PDF]

				S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase PNAS, February 27, 2007; 104(9): 3456 - 3459. [Abstract] [Full Text] [PDF]

				M. Olfson, S. C. Marcus, P. Corey-Lisle, A.V. Tuomari, P. Hines, and G. J. L'Italien Hyperlipidemia Following Treatment With Antipsychotic Medications Am J Psychiatry, October 1, 2006; 163(10): 1821 - 1825. [Abstract] [Full Text] [PDF]

				K. L. Olson, T. Delate, and D. J. Duagn Monitoring of Patients Given Second-Generation Antipsychotic Agents Psychiatr Serv, July 1, 2006; 57(7): 1045 - 1046. [Full Text] [PDF]

				E. M. Weissman, D. M. Moot, and S. M. Essock What Do People With Schizophrenia Think About Weight Management? Psychiatr Serv, May 1, 2006; 57(5): 724 - 725. [Full Text] [PDF]

				D. Cohen, R. P. Stolk, D. E. Grobbee, and C. C. Gispen-de Wied Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders Diabetes Care, April 1, 2006; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]

				F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 431 - 441. [Abstract] [Full Text] [PDF]

				P. A Marken and R. W Pies Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles Ann. Pharmacother., February 1, 2006; 40(2): 276 - 285. [Abstract] [Full Text] [PDF]

				M. D. Llorente and V. Urrutia Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications Clin. Diabetes, January 1, 2006; 24(1): 18 - 24. [Abstract] [Full Text] [PDF]

				R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen, J. P. McEvoy, S. M. Strakowski, T. Sharma, R. S. Kahn, R. E. Gur, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol The British Journal of Psychiatry, December 1, 2005; 187(6): 537 - 543. [Abstract] [Full Text] [PDF]

				C. Bushe and C. Paton The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol, November 1, 2005; 19(6_suppl): 76 - 83. [Abstract] [PDF]

				L. Citrome Metabolic Syndrome and Cardiovascular Disease J Psychopharmacol, November 1, 2005; 19(6_suppl): 84 - 93. [Abstract] [PDF]

				R. Freedman The Choice of Antipsychotic Drugs for Schizophrenia N. Engl. J. Med., September 22, 2005; 353(12): 1286 - 1288. [Full Text] [PDF]

				G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]

				T. A. Rugino and Y. M. Janvier Aripiprazole in Children and Adolescents: Clinical Experience J Child Neurol, July 1, 2005; 20(7): 603 - 610. [Abstract] [PDF]

				S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al. Physical Health Monitoring of Patients With Schizophrenia Am J Psychiatry, August 1, 2004; 161(8): 1334 - 1349. [Abstract] [Full Text] [PDF]

				H. Smith and T. White Low glycaemic index diet in patients prescribed clozapine: pilot study Psychiatr. Bull., August 1, 2004; 28(8): 292 - 294. [Abstract] [Full Text] [PDF]

				R.H. Belmaker Bipolar Disorder N. Engl. J. Med., July 29, 2004; 351(5): 476 - 486. [Full Text] [PDF]

				P. E Lee, S. S Gill, M. Freedman, S. E Bronskill, M. P Hillmer, and P. A Rochon Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review BMJ, July 10, 2004; 329(7457): 75. [Abstract] [Full Text] [PDF]

				C. Bushe and R. Holt Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia The British Journal of Psychiatry, April 1, 2004; 184(47): s67 - s71. [Abstract] [Full Text] [PDF]

				C. Bushe and B. Leonard Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data The British Journal of Psychiatry, April 1, 2004; 184(47): s87 - s93. [Abstract] [Full Text] [PDF]

				S. Gough and R. Peveler Diabetes and its prevention: pragmatic solutions for people with schizophrenia The British Journal of Psychiatry, April 1, 2004; 184(47): s106 - s111. [Abstract] [Full Text] [PDF]

				Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes Diabetes Care, February 1, 2004; 27(2): 596 - 601. [Full Text] [PDF]

				L. L Citrome and A. B Jaffe Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus Ann. Pharmacother., December 1, 2003; 37(12): 1849 - 1857. [Abstract] [Full Text] [PDF]

				R. Freedman Schizophrenia N. Engl. J. Med., October 30, 2003; 349(18): 1738 - 1749. [Full Text] [PDF]

				J. VOLAVKA, P. CZOBOR, J.-P. LINDENMAYER, L. CITROME, J. P. McEVOY, T. B. COOPER, and J. A. LIEBERMAN Dr. Volavka and Colleagues Reply Am J Psychiatry, March 1, 2003; 160(3): 592 - 593. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us